Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

K. Ribi, J. Aldridge, K. A. Phillips, A. Thompson, V. Harvey, B. Thürlimann, F. Cardoso, O. Pagani, A. S. Coates, A. Goldhirsch, K. N. Price, R. D. Gelber, J. Bernhard

Research output: Contribution to journalArticle

Abstract

Background: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF). Methods: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored. Results: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P=0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R0.80). Correlations between SCF and the other patient-reported outcomes were generally low. Conclusion: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute.

Original languageEnglish
Pages (from-to)1618-1625
Number of pages8
JournalBritish Journal of Cancer
Volume106
Issue number10
DOIs
Publication statusPublished - May 8 2012

Fingerprint

Cognition
Breast Neoplasms
letrozole
Therapeutics
Tamoxifen
Nonparametric Statistics
Fatigue
Quality of Life
Psychology

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • Letrozole
  • Quality of life
  • Subjective cognitive function
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ribi, K., Aldridge, J., Phillips, K. A., Thompson, A., Harvey, V., Thürlimann, B., ... Bernhard, J. (2012). Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. British Journal of Cancer, 106(10), 1618-1625. https://doi.org/10.1038/bjc.2012.156

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. / Ribi, K.; Aldridge, J.; Phillips, K. A.; Thompson, A.; Harvey, V.; Thürlimann, B.; Cardoso, F.; Pagani, O.; Coates, A. S.; Goldhirsch, A.; Price, K. N.; Gelber, R. D.; Bernhard, J.

In: British Journal of Cancer, Vol. 106, No. 10, 08.05.2012, p. 1618-1625.

Research output: Contribution to journalArticle

Ribi, K, Aldridge, J, Phillips, KA, Thompson, A, Harvey, V, Thürlimann, B, Cardoso, F, Pagani, O, Coates, AS, Goldhirsch, A, Price, KN, Gelber, RD & Bernhard, J 2012, 'Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer', British Journal of Cancer, vol. 106, no. 10, pp. 1618-1625. https://doi.org/10.1038/bjc.2012.156
Ribi, K. ; Aldridge, J. ; Phillips, K. A. ; Thompson, A. ; Harvey, V. ; Thürlimann, B. ; Cardoso, F. ; Pagani, O. ; Coates, A. S. ; Goldhirsch, A. ; Price, K. N. ; Gelber, R. D. ; Bernhard, J. / Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. In: British Journal of Cancer. 2012 ; Vol. 106, No. 10. pp. 1618-1625.
@article{42b6ccc1a7d14c0cb95d114938a29f0e,
title = "Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer",
abstract = "Background: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF). Methods: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored. Results: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P=0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R0.80). Correlations between SCF and the other patient-reported outcomes were generally low. Conclusion: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute.",
keywords = "Aromatase inhibitor, Breast cancer, Letrozole, Quality of life, Subjective cognitive function, Tamoxifen",
author = "K. Ribi and J. Aldridge and Phillips, {K. A.} and A. Thompson and V. Harvey and B. Th{\"u}rlimann and F. Cardoso and O. Pagani and Coates, {A. S.} and A. Goldhirsch and Price, {K. N.} and Gelber, {R. D.} and J. Bernhard",
year = "2012",
month = "5",
day = "8",
doi = "10.1038/bjc.2012.156",
language = "English",
volume = "106",
pages = "1618--1625",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

AU - Ribi, K.

AU - Aldridge, J.

AU - Phillips, K. A.

AU - Thompson, A.

AU - Harvey, V.

AU - Thürlimann, B.

AU - Cardoso, F.

AU - Pagani, O.

AU - Coates, A. S.

AU - Goldhirsch, A.

AU - Price, K. N.

AU - Gelber, R. D.

AU - Bernhard, J.

PY - 2012/5/8

Y1 - 2012/5/8

N2 - Background: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF). Methods: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored. Results: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P=0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R0.80). Correlations between SCF and the other patient-reported outcomes were generally low. Conclusion: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute.

AB - Background: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF). Methods: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored. Results: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P=0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R0.80). Correlations between SCF and the other patient-reported outcomes were generally low. Conclusion: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute.

KW - Aromatase inhibitor

KW - Breast cancer

KW - Letrozole

KW - Quality of life

KW - Subjective cognitive function

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84860779907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860779907&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.156

DO - 10.1038/bjc.2012.156

M3 - Article

C2 - 22531635

AN - SCOPUS:84860779907

VL - 106

SP - 1618

EP - 1625

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -